Global /Japan /Healthcare /Medical Devices /6869
chevron_leftBack

Sysmex Corp.

6869
TSE: 6869 Delayed
2,650JPY -0.7%
18.52 USD
As of 24 April 2025, Sysmex Corp. has a market cap of $11.6B USD, ranking #1495 globally and #107 in Japan. It ranks #124 in the Healthcare sector, and #16 in the Medical Devices industry.
Global Rank
1495
Country Rank
107
Sector Rank
124
Industry Rank
16
Key Stats
Market Cap
$11.6BUSD
1.65T JPY
Enterprise Value
$11.4BUSD
1.63T JPY
Revenue (TTM)
$3.52BUSD
501.85B JPY
EBITDA (TTM)
$919.79MUSD
131.63B JPY
Net Income (TTM)
$405.57MUSD
57.79B JPY
EBITDA Margin
26%
Profit Margin
12%
PE Ratio
28.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Kaoru Asano open_in_new
Employees
10,042
Founded
1968
Website
sysmex.co.jp open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-0.7% -1.3% -6.4% -9.3% -6% 8.9%
Upcoming Earnings
Earnings Date
Wed, May 14

Markets

Exchange Ticker Price
Tokyo Stock Exchange
MIC: XTKS
PRIMARY
6869
シスメックス株式会社
ISIN: JP3351100007
Shares Out.:
623.6M1 Shares Float: 442.85M2
TV:
SA:
YF:
GF:
BA:
MS:
2.65K JPY
Mexican Bolsa
MIC: XMEX
6869 (6869/N)
シスメックス株式会社
ISIN: JP3351100007
TV:
SA:
YF:
GF:
BA:
MS:
377.38 MXN
OTC Markets
MIC: OTCM
SSMXF
シスメックス株式会社
ISIN: JP3351100007
TV:
SA:
YF:
GF:
BA:
MS:
18.85 USD
OTC Markets
MIC: OTCM
SSMXY
シスメックス株式会社 ADR
ISIN: US87184P1093
TV:
SA:
YF:
GF:
BA:
MS:
18.75 USD
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Sysmex Corp.

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software in Japan. It offers three-part and five-part white blood cell differentiation instruments for use in hematology; and transport systems for high-volume testing in labs. The company also provides automated urine particle analyzers; automated blood coagulation analyzers; automated immunochemistry systems, which perform assays on minute sample quantities, as well as reagents to test for infectious disease and tumor markers; and flow cytometers to perform analysis in diagnosing leukemia, malignant lymphoma, and HIV/AIDS. In addition, it offers cancer lymph node metastasis testing systems to detect information to help in diagnosing lymph node metastasis; and lab assay services. Further, the company is involved in the development and sale of software for diagnostic information systems; provision of facility management, office, welfare, and genetic analysis services; development, operation, and maintenance of IT solutions, platforms, and applications related to digital medicine; marketing, development, design, manufacture, sale, and after-sales service related to medical robots; and distribution and after sales support of medical devices and reagents for biotechnology, medical technology, and molecular cell analysis. Additionally, it researches, develops, manufactures, and sells regenerative medicine products; develops, manufactures, and sells biodevices; develops, maintains, and sells computer software; and offers blood DNA testing service. The company serves national and other public hospitals, private hospitals, universities, research institutes, other medical institutions, etc. It also exports its products to approximately 190 countries. The company was formerly known as TOA Medical Electronics Co., Ltd. and changed its name to Sysmex Corporation in October 1998. Sysmex Corporation was founded in 1968 and is headquartered in Kobe, Japan.

Similar Companies

Industry: Medical Devices (Japan)
Name
Market Cap diff.
Olympus Corp.
7733
$14.34B
2.04T JPY
24%
Nihon Kohden Corp.
6849
$1.99B
283.98B JPY
-83%
Fukuda Denshi Co., Ltd.
6960
$1.21B
172.68B JPY
-90%
PHC Holdings Corp.
6523
$856.36M
122.02B JPY
-93%
Japan Lifeline Co., Ltd.
7575
$756.62M
107.81B JPY
-93%
Industry: Medical Devices (Global)
Name
Market Cap diff.
Abbott Laboratories
ABT
$225.18B
2K%
Boston Scientific Corp.
BSX
$146.31B
1K%
Stryker Corp.
SYK
$136.3B
1K%
Medtronic plc
MDT
$107.41B
826%
Siemens Healthineers AG
SHL
$57.76B
50.97B EUR
398%